Core Scientific (NASDAQ:CORZ) reported quarterly losses of $(3.32) per share which missed the analyst consensus estimate of $(0.10) by 3220 percent. This is a 4050 percent decrease over losses of $(0.08) per share from the same period last year. The company reported quarterly sales of $164.201 million which beat the analyst consensus estimate of $143.054 million by 14.78 percent. This is a 108.83 percent increase over sales of $78.628 million the same period last year.